Simon Vyse

1.6k total citations · 1 hit paper
17 papers, 1.1k citations indexed

About

Simon Vyse is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Simon Vyse has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Simon Vyse's work include Lung Cancer Treatments and Mutations (5 papers), Cancer therapeutics and mechanisms (3 papers) and interferon and immune responses (2 papers). Simon Vyse is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer therapeutics and mechanisms (3 papers) and interferon and immune responses (2 papers). Simon Vyse collaborates with scholars based in United Kingdom, United States and Germany. Simon Vyse's co-authors include Paul H. Huang, Aik Choon Tan, Timothy J. Vyse, Myles Lewis, Adrian Shields, Patrick Gordon, Andrew Jenks, Sebastian Boeltz, Paul J. Lehner and Henning Walczak and has published in prestigious journals such as The Lancet, Journal of Molecular Biology and The American Journal of Human Genetics.

In The Last Decade

Simon Vyse

17 papers receiving 1.1k citations

Hit Papers

Rare epidermal growth factor receptor (EGFR) mutations in... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
    2019 397 citations Simon Vyse, Paul H. Huang et al. Seminars in Cancer Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simon Vyse United Kingdom 15 532 525 489 219 125 17 1.1k
Chuifeng Fan China 20 694 1.3× 331 0.6× 366 0.7× 238 1.1× 97 0.8× 77 1.2k
Martina Kluth Germany 22 768 1.4× 644 1.2× 327 0.7× 415 1.9× 84 0.7× 75 1.3k
Yuehong Cui China 21 681 1.3× 370 0.7× 530 1.1× 317 1.4× 154 1.2× 79 1.4k
Philippe Haas Switzerland 8 588 1.1× 230 0.4× 578 1.2× 207 0.9× 155 1.2× 8 1.1k
Anh Hoang United States 18 615 1.2× 983 1.9× 433 0.9× 465 2.1× 148 1.2× 47 1.5k
M. Beeram United States 16 406 0.8× 304 0.6× 452 0.9× 169 0.8× 58 0.5× 48 860
Emmy D.G. Fleuren Netherlands 17 497 0.9× 307 0.6× 368 0.8× 108 0.5× 76 0.6× 25 871
Ubaradka G. Sathyanarayana United States 17 1.1k 2.0× 498 0.9× 276 0.6× 323 1.5× 88 0.7× 22 1.4k
Kathryn E. Ware United States 16 870 1.6× 513 1.0× 548 1.1× 399 1.8× 171 1.4× 27 1.5k
Paul R. Gavine China 15 928 1.7× 407 0.8× 408 0.8× 242 1.1× 65 0.5× 29 1.4k

Countries citing papers authored by Simon Vyse

Since Specialization
Citations

This map shows the geographic impact of Simon Vyse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Vyse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Vyse more than expected).

Fields of papers citing papers by Simon Vyse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Vyse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Vyse. The network helps show where Simon Vyse may publish in the future.

Co-authorship network of co-authors of Simon Vyse

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Vyse. A scholar is included among the top collaborators of Simon Vyse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Vyse. Simon Vyse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Jenks, Andrew, et al.. (2021). Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer. Pharmacogenomics and Personalized Medicine. Volume 14. 301–317. 21 indexed citations
2.
Vyse, Simon & Paul H. Huang. (2021). Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. Expert Review of Anticancer Therapy. 22(1). 3–16. 21 indexed citations
3.
Vyse, Simon, Khin Thway, Paul H. Huang, & Robin L. Jones. (2021). Next-generation sequencing for the management of sarcomas with no known driver mutations. Current Opinion in Oncology. 33(4). 315–322. 16 indexed citations
4.
Vyse, Simon & Paul H. Huang. (2019). Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduction and Targeted Therapy. 4(1). 5–5. 243 indexed citations
5.
Vyse, Simon, et al.. (2019). Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Seminars in Cancer Biology. 61. 167–179. 397 indexed citations breakdown →
6.
Jenks, Andrew, Simon Vyse, Eleftherios Kostaras, et al.. (2018). Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer. Cell Reports. 23(10). 3042–3055. 89 indexed citations
7.
Vyse, Simon, H. Desmond, & Paul H. Huang. (2017). Advances in mass spectrometry based strategies to study receptor tyrosine kinases. IUCrJ. 4(2). 119–130. 12 indexed citations
8.
Vyse, Simon, et al.. (2017). Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. Journal of Molecular Biology. 429(12). 1767–1786. 13 indexed citations
9.
Vyse, Simon, Frank McCarthy, Malgorzata Broncel, et al.. (2017). Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. Journal of Proteomics. 170. 130–140. 24 indexed citations
10.
Pullabhatla, Venu, Amy L. Roberts, Myles Lewis, et al.. (2017). De novo mutations implicate novel genes in systemic lupus erythematosus. Human Molecular Genetics. 27(3). 421–429. 35 indexed citations
11.
Lewis, Myles, Simon Vyse, Adrian Shields, et al.. (2016). Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1. Arthritis Research & Therapy. 18(1). 5–5. 20 indexed citations
12.
Tan, Aik Choon, Simon Vyse, & Paul H. Huang. (2016). Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discovery Today. 22(1). 72–84. 30 indexed citations
13.
Todd, Jason R., Martina Finetti, Frank McCarthy, et al.. (2016). Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. Cell Reports. 17(5). 1265–1275. 40 indexed citations
14.
Todd, Jason R., Karen A. Ryall, Simon Vyse, et al.. (2016). Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. Oncotarget. 7(39). 62939–62953. 29 indexed citations
15.
Maguire, Sarah, Barrie Peck, Patty T. Wai, et al.. (2016). Three‐dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. The Journal of Pathology. 240(3). 315–328. 31 indexed citations
16.
Lewis, Myles, Simon Vyse, Adrian Shields, et al.. (2015). Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus. The Lancet. 385. S9–S9. 15 indexed citations
17.
Lewis, Myles, Simon Vyse, Adrian Shields, et al.. (2015). UBE2L3 Polymorphism Amplifies NF-κB Activation and Promotes Plasma Cell Development, Linking Linear Ubiquitination to Multiple Autoimmune Diseases. The American Journal of Human Genetics. 96(2). 221–234. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chuifeng Fan Breakdown of academic impact, for papers by Martina Kluth Breakdown of academic impact, for papers by Yuehong Cui Breakdown of academic impact, for papers by Philippe Haas Breakdown of academic impact, for papers by Anh Hoang Breakdown of academic impact, for papers by M. Beeram Breakdown of academic impact, for papers by Emmy D.G. Fleuren Breakdown of academic impact, for papers by Ubaradka G. Sathyanarayana Breakdown of academic impact, for papers by Kathryn E. Ware Breakdown of academic impact, for papers by Paul R. Gavine
Rankless by CCL
2026